The CD47-targeted antibody magrolimab (5F9) has shown robust clinical activity in combination with azacitidine in an ongoing phase 1 study in patients with intermediate- to very high-risk MDS (NCT03248479 [114]), particularly in patients with TP53 mutations; expansion cohorts are ongoing, and registration trials in MDS are being initiated. This evidence concerns the gene CD47 and myelodysplastic syndrome.